Canine Monocytic Ehrlichiosis

Canine monocytic ehrlichiosis (CME) is a tick-borne infectious disease caused by the obligate intracellular gram-negative bacterium Ehrlichia canis, which primarily infects circulating monocytes and macrophages. The disease is characterized by a triphasic clinical course: acute, subclinical, and chronic phases. Acute phase typically presents with fever, lethargy, thrombocytopenia, and lymphadenopathy, while the chronic phase may manifest as severe pancytopenia, bleeding diathesis, and secondary infections due to profound immunosuppression. CME is a multisystemic disease affecting the hematopoietic, reticuloendothelial, and vascular systems, and can be fatal if untreated. The disease is also known as tropical canine pancytopenia, reflecting its global distribution in tropical and subtropical regions.

The primary causative agent is Ehrlichia canis, a small, obligately intracellular, gram-negative bacterium belonging to the family Anaplasmataceae. It is transmitted primarily by the brown dog tick, Rhipicephalus sanguineus, which serves as both vector and reservoir. Transmission occurs through the saliva of infected ticks during feeding, typically requiring 3-6 hours of attachment. Other Ehrlichia species, such as E. ewingii (which infects granulocytes) and E. chaffeensis (which infects monocytes), can also cause ehrlichiosis in dogs, but E. canis is the most clinically significant. The organism's virulence is attributed to its ability to evade the host immune response by modulating monocyte apoptosis, downregulating MHC class II expression, and surviving within phagosomes. The outer membrane proteins (OMPs) and tandem repeat proteins (TRPs) are key antigens involved in pathogenesis and immune evasion.

Canine monocytic ehrlichiosis has a worldwide distribution, with higher prevalence in tropical and subtropical regions, including the Mediterranean basin, Africa, Asia, Australia, and the Americas. In the United States, it is most common in the southeastern and south-central states, with prevalence rates varying from 1% to over 50% in endemic areas. The disease affects dogs of all ages, breeds, and sexes, but German Shepherd Dogs and Doberman Pinschers are reported to be more susceptible to severe chronic disease, possibly due to genetic predisposition in immune response. The incidence is seasonal, peaking during warm months when tick activity is highest. The brown dog tick is adapted to both indoor and outdoor environments, facilitating transmission in kennels and households. Co-infections with other tick-borne pathogens (e.g., Anaplasma spp., Babesia spp., Bartonella spp.) are common and can complicate diagnosis and treatment.

After inoculation via tick bite, E. canis infects circulating monocytes and tissue macrophages, where it replicates within phagosomes, forming morulae. Infected cells migrate to the spleen, liver, lymph nodes, and bone marrow, leading to widespread reticuloendothelial hyperplasia. The acute phase is characterized by a robust innate immune response with release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), resulting in fever, lethargy, and acute-phase protein production. Thrombocytopenia, a hallmark of acute ehrlichiosis, results from immune-mediated destruction of platelets, increased platelet consumption due to vasculitis, and decreased platelet production secondary to bone marrow suppression. As the disease progresses to the subclinical phase, the immune response may control the infection, but the organism persists in the spleen and bone marrow, leading to chronic antigenic stimulation. In the chronic phase, severe bone marrow suppression occurs due to myelofibrosis, aplastic anemia, and pancytopenia, likely mediated by persistent infection and immune dysregulation. Vasculitis and endothelial damage contribute to bleeding diathesis, edema, and organ dysfunction. Secondary infections are common due to immunosuppression from neutropenia and lymphocyte dysfunction.

Intrinsic risk factors include breed predisposition (German Shepherd Dogs, Doberman Pinschers) for severe chronic disease, possibly due to genetic differences in immune response. Age is a factor, with young dogs (<2 years) and older dogs (>8 years) being more susceptible to severe clinical signs. Extrinsic factors include exposure to tick-infested environments, lack of tick control measures, and co-infections with other tick-borne pathogens. Immunosuppressive therapy (e.g., corticosteroids) may exacerbate the disease. Poor nutrition and overcrowded housing conditions (e.g., kennels) increase the risk of tick infestation and transmission. Concurrent diseases, such as ehrlichiosis in dogs with chronic kidney disease or diabetes mellitus, may worsen the prognosis.

Clinical signs vary depending on the phase of infection. Acute phase (1-3 weeks post-infection): fever (103-106°F), lethargy, anorexia, lymphadenomegaly, splenomegaly, and sometimes petechial or ecchymotic hemorrhages due to thrombocytopenia. Ocular signs may include uveitis, retinal hemorrhages, and conjunctivitis. Neurological signs (e.g., seizures, ataxia) can occur due to meningitis or vasculitis. Subclinical phase: Dogs may appear clinically normal but have persistent thrombocytopenia, hyperglobulinemia, and positive serology. This phase can last months to years. Chronic phase: Severe signs include profound depression, weight loss, pale mucous membranes (anemia), bleeding diathesis (epistaxis, melena, hematuria), peripheral edema, and signs of secondary infections (pneumonia, urinary tract infections). Neurological signs (meningitis, paresis) and ocular signs (anterior uveitis, chorioretinitis) are more common. In some dogs, chronic ehrlichiosis manifests as a glomerulonephropathy with proteinuria and renal failure.

Differential diagnoses include: 1) Anaplasmosis (Anaplasma phagocytophilum or A. platys) - similar tick-borne transmission, but granulocytic or thrombocytic tropism; can be differentiated by PCR and serology. 2) Babesiosis (Babesia canis, B. gibsoni) - causes hemolytic anemia and thrombocytopenia; identified by blood smear or PCR. 3) Rocky Mountain Spotted Fever (Rickettsia rickettsii) - causes fever, rash, and thrombocytopenia; history of tick exposure and serology/PCR. 4) Systemic lupus erythematosus (SLE) - autoimmune disease with polyarthritis, glomerulonephritis, and positive ANA; distinguished by absence of tick exposure and specific autoantibodies. 5) Immune-mediated thrombocytopenia (ITP) - primary immune destruction of platelets; negative for Ehrlichia serology/PCR. 6) Multiple myeloma - causes hyperglobulinemia, cytopenias, and bone lesions; distinguished by monoclonal gammopathy and plasma cell infiltration in bone marrow. 7) Canine distemper - causes respiratory, gastrointestinal, and neurological signs; distinguished by viral antigen/PCR and characteristic intracytoplasmic inclusions. 8) Leishmaniasis - endemic in Mediterranean regions, causes fever, lymphadenopathy, skin lesions, and renal disease; diagnosed by cytology, serology, or PCR.

The diagnostic approach begins with a thorough history (tick exposure, travel) and physical examination. Initial screening includes a complete blood count (CBC) and serum biochemistry profile. Thrombocytopenia (often <50,000/µL) is a key finding. Blood smear examination may reveal morulae in monocytes (in acute phase) but is insensitive. Serological testing for antibodies against E. canis (IFA or ELISA) is widely used; a four-fold rise in titer over 2-4 weeks confirms active infection. However, antibodies may not be detectable in the first 7-14 days. PCR on whole blood or splenic aspirates is highly sensitive and specific, especially in the acute phase. In chronic cases, bone marrow cytology or biopsy may be needed to evaluate for myelofibrosis or aplasia. Additional tests include Coombs test (to rule out immune-mediated hemolytic anemia), antinuclear antibody (ANA) test (to rule out SLE), and tick-borne disease panels (e.g., IDEXX 4Dx) that include E. canis antibodies. In endemic areas, a positive serology in a dog with compatible clinical signs is often sufficient for diagnosis, but PCR is recommended for confirmation.

Hematology: Thrombocytopenia is the most consistent finding, often severe (<50,000/µL). Anemia (non-regenerative or regenerative) may be present due to blood loss, hemolysis, or bone marrow suppression. Leukopenia (neutropenia, lymphopenia) is common in acute and chronic phases. In chronic cases, pancytopenia may be observed. Blood smear may show morulae in monocytes (rare). Serum biochemistry: Hyperglobulinemia (polyclonal) is common, especially in subclinical and chronic phases. Hypoalbuminemia may occur due to protein-losing nephropathy or liver disease. Elevated liver enzymes (ALT, ALP) may be seen due to hepatic inflammation. Azotemia (elevated BUN, creatinine) may indicate renal involvement. Urinalysis: Proteinuria (UPC >0.5) may be present due to glomerulonephritis. Active sediment may show hematuria or pyuria. Blood gas analysis: May reveal metabolic acidosis in severe systemic disease. Specific biomarkers: C-reactive protein (CRP) is elevated in acute phase. Serum amyloid A (SAA) may also be elevated. Serology: IFA or ELISA for E. canis antibodies; titers ≥1:80 are considered positive. PCR: Positive in acute and subclinical phases; may be negative in chronic phase due to low organism load.

Radiography: Thoracic radiographs may show interstitial or alveolar patterns if secondary pneumonia is present. Abdominal radiographs may reveal hepatosplenomegaly. Ultrasonography: Abdominal ultrasound often shows splenomegaly, hepatomegaly, and generalized lymphadenomegaly. In chronic cases, renal changes (increased echogenicity, loss of corticomedullary distinction) may be seen. Echocardiography: Not typically indicated unless cardiac involvement is suspected. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI): May be used to evaluate for meningoencephalitis in dogs with neurological signs, showing contrast enhancement of meninges or brain lesions. Endoscopy: Not routinely used, but may be helpful to evaluate for gastrointestinal bleeding.

Cytology: Fine needle aspirates of lymph nodes, spleen, or bone marrow may reveal increased numbers of plasma cells and macrophages. Morulae may be seen in monocytes in acute cases. Bone marrow aspirates in chronic cases may show hypocellularity, myelofibrosis, or aplasia. Histopathology: Splenic biopsy shows reticuloendothelial hyperplasia, plasma cell infiltration, and erythrophagocytosis. Liver biopsy may show periportal lymphoplasmacytic inflammation. Bone marrow biopsy reveals myelofibrosis, aplasia, or necrosis. Immunohistochemistry (IHC) using anti-E. canis antibodies can confirm the presence of organisms in tissues. Special stains (e.g., Giemsa) may highlight morulae.

The treatment of choice for canine monocytic ehrlichiosis is doxycycline. The recommended dosage is 5 mg/kg PO q12h or 10 mg/kg PO q24h for a minimum of 28 days. In severe acute cases, doxycycline may be administered IV initially (5 mg/kg IV q12h) until oral medication is tolerated. Alternative antibiotics include minocycline (5 mg/kg PO q12h) or oxytetracycline (22 mg/kg PO q8h), but doxycycline is preferred due to better tissue penetration and tolerability. In chronic cases with severe pancytopenia, treatment may be prolonged (up to 8 weeks) and may require supportive care. Supportive therapy includes IV fluids (e.g., lactated Ringer's solution at 60-100 mL/kg/day) for dehydration and shock. Blood transfusions (packed red blood cells or whole blood) may be necessary for severe anemia (PCV <15%) or bleeding. Glucocorticoids (e.g., prednisone 0.5-1 mg/kg PO q12h) may be used in cases with severe immune-mediated thrombocytopenia or vasculitis, but should be used cautiously as they may exacerbate immunosuppression. Secondary infections should be treated with appropriate antibiotics. Tick control is essential to prevent reinfection. In endemic areas, prophylactic doxycycline (3-5 mg/kg PO q24h) may be considered during high-risk seasons.

The prognosis for acute ehrlichiosis is generally good with prompt treatment; most dogs show clinical improvement within 24-48 hours and hematologic recovery within 1-2 weeks. The subclinical phase has a guarded prognosis as dogs may remain persistently infected and can progress to chronic disease. Chronic ehrlichiosis has a guarded to poor prognosis, especially if severe pancytopenia, myelofibrosis, or secondary infections are present. Mortality rates in chronic cases can be as high as 50%. Negative prognostic indicators include severe thrombocytopenia (<20,000/µL), pancytopenia, hypoalbuminemia, azotemia, and lack of response to doxycycline within 7 days. Dogs that recover may have persistent antibody titers but are considered clinically cured if PCR becomes negative. Recurrence is possible if tick exposure continues.

Recheck examinations should be performed at 7, 14, 28, and 56 days after initiation of treatment. At each visit, a CBC and serum biochemistry profile should be repeated to monitor platelet count, anemia, and globulin levels. PCR for E. canis should be repeated at 28 and 56 days to confirm clearance of the organism. If PCR remains positive after 56 days, consider extending treatment or investigating for co-infections. Long-term monitoring (every 3-6 months) is recommended for dogs that have recovered from chronic ehrlichiosis, including urinalysis and UPC to monitor for proteinuria. Tick control measures should be maintained year-round. In endemic areas, annual serology testing may be considered.

Pearls: 1) Thrombocytopenia is a hallmark of ehrlichiosis; any dog with fever and thrombocytopenia in a tick-endemic area should be tested for E. canis. 2) Doxycycline is the drug of choice; do not use fluoroquinolones as monotherapy as they are less effective. 3) In chronic cases, bone marrow biopsy may be necessary to differentiate from other causes of pancytopenia. 4) Co-infections with other tick-borne pathogens are common; consider testing for Anaplasma, Babesia, and Bartonella. 5) Glucocorticoids should be used with caution; they may worsen the infection. Pitfalls: 1) Serology may be negative in the acute phase; PCR is more sensitive. 2) Do not rely solely on blood smear for diagnosis; morulae are rarely seen. 3) In chronic cases, PCR may be negative; diagnosis may rely on serology and response to treatment. 4) Do not discontinue doxycycline prematurely; a minimum of 28 days is required. 5) In severe thrombocytopenia, avoid jugular venipuncture and consider using a smaller gauge needle to minimize bleeding.

Based on Plumb's Veterinary Drug Handbook: Doxycycline: 5 mg/kg PO q12h or 10 mg/kg PO q24h for 28 days; IV formulation (10 mg/mL) can be given at 5 mg/kg IV q12h, but must be diluted and given slowly over 30-60 minutes to avoid phlebitis. Minocycline: 5 mg/kg PO q12h for 28 days. Oxytetracycline: 22 mg/kg PO q8h for 28 days (less preferred). Imidocarb dipropionate: 6.6 mg/kg IM or SC once, repeated in 14 days, may be used for concurrent Babesia infection. Prednisone: 0.5-1 mg/kg PO q12h for 7-14 days, then taper, if severe immune-mediated complications. Supportive care: IV fluids (Lactated Ringer's or Normosol-R) at 60-100 mL/kg/day, adjusted based on hydration status. Blood transfusion: 10-20 mL/kg of packed red blood cells or fresh whole blood over 4-6 hours. Antiemetics (e.g., maropitant 1 mg/kg SC q24h) if vomiting. Gastroprotectants (e.g., omeprazole 1 mg/kg PO q12h) if GI bleeding. In renal impairment, doxycycline dose adjustment is not necessary, but caution with IV administration. Contraindications: Doxycycline should not be used in puppies <6 months of age due to tooth discoloration; alternatives include minocycline. Drug interactions: Doxycycline may reduce the efficacy of oral contraceptives and increase the risk of esophageal irritation; administer with food and water.

Key studies and consensus guidelines: 1) The ACVIM consensus statement on the diagnosis and treatment of tick-borne diseases in dogs and cats (2018) recommends doxycycline as the first-line treatment for ehrlichiosis, with a duration of at least 28 days. 2) A study by Harrus et al. (1998) demonstrated that doxycycline at 10 mg/kg/day for 21 days was effective in eliminating E. canis infection in experimentally infected dogs. 3) A study by Neer et al. (2002) evaluated the efficacy of doxycycline (5 mg/kg q12h) for 28 days and found that 100% of dogs became PCR-negative by day 28. 4) A retrospective study by Mylonakis et al. (2004) found that chronic ehrlichiosis with pancytopenia had a poor prognosis, with a mortality rate of 50%. 5) A study by Gaunt et al. (2010) showed that co-infection with E. canis and Babesia canis resulted in more severe clinical signs and thrombocytopenia. 6) The use of glucocorticoids in ehrlichiosis is controversial; a study by Harrus et al. (1998) suggested that prednisone may exacerbate the disease, so it should only be used for severe immune-mediated complications. 7) A recent study by Little et al. (2018) evaluated the use of a point-of-care ELISA for E. canis antibodies and found it to be highly sensitive and specific. 8) The ISCAID guidelines (2017) recommend PCR as the preferred diagnostic test for acute ehrlichiosis, with serology for screening in endemic areas.